NEW YORK (GenomeWeb) – Microbial genetics analysis firm OpGen plans to offer 3.75 million shares of its common stock for its planned initial public offering, the company said in an amended Form S-1 today. 

The company said that it plans to offer its stock at a price between $8 and $10 per share. At the midpoint price of $9, OpGen anticipates the IPO will bring in net proceeds of about $30.5 million, or $35.2 million if the offering's underwriter exercises its overallotment option in full. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.